XETRA - Delayed Quote EUR

BRAIN Biotech AG (BNN.DE)

2.0600
-0.0100
(-0.48%)
At close: May 9 at 5:36:17 PM GMT+2
Loading Chart for BNN.DE
  • Previous Close 2.0700
  • Open 2.1600
  • Bid 2.0300 x 133300
  • Ask 2.1300 x 40000
  • Day's Range 2.0300 - 2.1600
  • 52 Week Range 1.4150 - 4.4000
  • Volume 740
  • Avg. Volume 7,554
  • Market Cap (intraday) 45.006M
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5700
  • Earnings Date May 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.99

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates through three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. The company was founded in 1993 and is headquartered in Zwingenberg, Germany.

www.brain-biotech.com

296

Full Time Employees

September 30

Fiscal Year Ends

Recent News: BNN.DE

View More

Performance Overview: BNN.DE

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

BNN.DE
40.29%
DAX P (^GDAXI)
18.03%

1-Year Return

BNN.DE
25.09%
DAX P (^GDAXI)
25.75%

3-Year Return

BNN.DE
72.39%
DAX P (^GDAXI)
75.62%

5-Year Return

BNN.DE
76.96%
DAX P (^GDAXI)
115.50%

Compare To: BNN.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BNN.DE

View More

Valuation Measures

As of 5/9/2025
  • Market Cap

    45.01M

  • Enterprise Value

    30.52M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.82

  • Price/Book (mrq)

    4.98

  • Enterprise Value/Revenue

    0.55

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.42%

  • Return on Assets (ttm)

    -8.19%

  • Return on Equity (ttm)

    -81.22%

  • Revenue (ttm)

    55.82M

  • Net Income Avi to Common (ttm)

    -12.52M

  • Diluted EPS (ttm)

    -0.5700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    17.82M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    826.62k

Research Analysis: BNN.DE

View More

People Also Watch